Everolimus and sorafenib

DRUG2 trials

Sponsors

Andrea Harzstark, Hospices Civils de Lyon

Conditions

Locally Metastatic Malignant NeoplasmMetastatic or Locally Advanced Solid Tumors

Phase 1

EVESOR: a Phase 1 Trial of Everolimus and Sorafenib

Hospices Civils de LyonMetastatic or Locally Advanced Solid Tumors

Start: 2013-04-30End: 2015-10-31Target: 60Updated: 2013-08-30

Phase 2

Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)

WithdrawnNCT01616186

Andrea HarzstarkLocally Metastatic Malignant Neoplasm

Start: 2012-07-31End: 2016-04-30Updated: 2013-04-08

Related Papers

A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.

2023-04-031 citations

Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.

2023-02-254 citations

Abstract CT148: Clinical results of the multiparameter phase 1 trial EVESOR meant to optimize the doses and dosing schedules of the combination EVErolimus and SORafenib in solid tumors

Cancer Research2020-08-15

EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib.

2017-01-124 citations

EVESOR, the first model-based multi-parameter academic phase 1 trial meant to optimize the benefit/toxicity ratio of everolimus (EVE) and sorafenib (SOR) combination: Initial results.

Journal of Clinical Oncology2016-05-20